Arrowhead Pharmaceuticals
biopharmaceutical company
ARWR Nasdaq
SEC CIK 879407 LEI 549300O3CSB8T7OZ3D66
Follow Arrowhead Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$37.8M
−85.3% vs same quarter last year
Net income
−$428M
−1702.1% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$192.4M
−1039% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $450.8M | −$724.2M |
| FY25 | $829.4M | −$1.6M |
| FY24 | $3.6M | −$599.5M |
| FY23 | $240.7M | −$205.3M |
| FY22 | $243.2M | −$176.1M |
| FY21 | $138.3M | −$140.8M |
| FY20 | $88M | −$84.6M |
| FY19 | $168.8M | $68M |
| FY18 | $16.1M | −$54.5M |
| FY17 | $31.4M | −$34.4M |
| FY16 | $158.3K | −$81.7M |
| FY15 | $382K | −$91.9M |
| FY14 | $175K | −$58.6M |
| FY13 | $290.3K | −$31.1M |
| FY12 | $146.9K | −$21.1M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY26 | −156.9% | −160.6% |
| FY25 | 11.9% | −0.2% |
| FY24 | −16927.1% | −16882.4% |
| FY23 | −85.2% | −85.3% |
| FY22 | −73.4% | −72.4% |
| FY21 | −107.8% | −101.9% |
| FY20 | −105.9% | −96.1% |
| FY19 | 36.3% | 40.3% |
| FY18 | −346.5% | −337.3% |
| FY17 | −117.8% | −109.5% |
| FY16 | −51627.1% | −51614.6% |
| FY15 | −25124.1% | −24068.3% |
| FY14 | −30443.6% | −33503% |
| FY13 | −8471.3% | −10729.2% |
| FY12 | −14358.6% | −14383.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | −$283.9M |
| FY25 | $156.9M |
| FY24 | −$604.3M |
| FY23 | −$330.6M |
| FY22 | −$188.9M |
| FY21 | $147.7M |
| FY20 | −$107.8M |
| FY19 | $161M |
| FY18 | −$48.6M |
| FY17 | −$31.9M |
| FY16 | −$68.3M |
| FY15 | −$67.7M |
| FY14 | −$37.1M |
| FY13 | −$19.3M |
| FY12 | −$15.8M |
- Arrowhead Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Arrowhead Pharmaceuticals | Healthcare median |
|---|---|---|
| FY26 | −160.6% | −11.1% |
| FY25 | −0.2% | −30.6% |
| FY24 | −16882.4% | −47% |
| FY23 | −85.3% | −58% |
| FY22 | −72.4% | −80.4% |
| FY21 | −101.9% | −71.9% |
| FY20 | −96.1% | −62.2% |
| FY19 | 40.3% | −46.3% |
| FY18 | −337.3% | −49.6% |
| FY17 | −109.5% | −45.9% |
| FY16 | −51614.6% | −36% |
| FY15 | −24068.3% | −38.4% |
| FY14 | −33503% | −35.5% |
| FY13 | −10729.2% | −37.1% |
| FY12 | −14383.6% | −29.1% |